Sequoia Financial Advisors LLC Acquires Shares of 5,140 Cencora, Inc. (NYSE:COR)

Sequoia Financial Advisors LLC purchased a new position in shares of Cencora, Inc. (NYSE:COR) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 5,140 shares of the company’s stock, valued at approximately $1,249,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Diversify Advisory Services LLC bought a new position in shares of Cencora during the 1st quarter worth $1,492,000. Private Advisor Group LLC purchased a new position in Cencora during the 1st quarter valued at about $1,479,000. J.W. Cole Advisors Inc. purchased a new position in Cencora during the 1st quarter valued at about $906,000. Retirement Systems of Alabama purchased a new position in Cencora during the 1st quarter valued at about $8,880,000. Finally, Van ECK Associates Corp purchased a new position in Cencora during the 1st quarter valued at about $42,098,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of research analyst reports. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. Robert W. Baird lifted their price target on Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Citigroup lifted their price target on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Finally, SVB Leerink restated an “outperform” rating and issued a $275.00 target price on shares of Cencora in a research report on Thursday, June 27th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $235.30.

Insider Activity

In other news, CEO Steven H. Collis sold 10,754 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total transaction of $2,553,859.92. Following the transaction, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $67,702,698.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Dermot Mark Durcan purchased 500 shares of Cencora stock in a transaction that occurred on Friday, May 24th. The shares were bought at an average cost of $218.58 per share, with a total value of $109,290.00. Following the completion of the purchase, the director now directly owns 21,876 shares in the company, valued at $4,781,656.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven H. Collis sold 10,754 shares of the company’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at $67,702,698.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,956,675 shares of company stock valued at $422,352,056. Company insiders own 15.80% of the company’s stock.

Cencora Trading Up 0.1 %

COR stock traded up $0.18 during midday trading on Friday, hitting $222.68. The company had a trading volume of 830,619 shares, compared to its average volume of 1,547,650. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.41. Cencora, Inc. has a 52 week low of $171.65 and a 52 week high of $246.75. The stock’s 50 day moving average price is $227.53 and its 200 day moving average price is $228.55. The stock has a market cap of $44.41 billion, a price-to-earnings ratio of 24.36, a PEG ratio of 1.55 and a beta of 0.45.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The firm had revenue of $68.41 billion for the quarter, compared to analysts’ expectations of $70.60 billion. During the same period in the previous year, the firm earned $3.50 earnings per share. The business’s revenue was up 7.8% compared to the same quarter last year. As a group, equities research analysts expect that Cencora, Inc. will post 13.44 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 10th were paid a dividend of $0.51 per share. The ex-dividend date was Thursday, May 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.92%. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.